Latest news
Darlifarnib Plus Cabozantinib Shows Durable Activity in Advanced RCC - Targeted OncologyTargeted Oncology · Mon, 27 Jul 2026 15:10:16 GMTKura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma - quiverquant.comquiverquant.com · Mon, 27 Jul 2026 10:40:00 GMTKura's Drug Combo Shows 13-Month Median Without Progression - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMT